Biotechnology

Pieris Pharmaceuticals to Participate in the Cowen 41st Annual Health Care Conference

February 23, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / February 23, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that Stephen S. Yoder, President and Chief Executive Officer of Pieris, is scheduled to participate in a GI Oncology and Pancreatic Cancer panel discussion at...

Read more

CB Scientific, Inc. Announces Definitive Agreement to Acquire Cardiolink Corporation, an Independent Diagnostic Testing Facility (IDTF)

February 23, 2021 7:30 AM

Addition of IDTF operation has CBSC well-positioned to significantly impact the US Remote Patient Monitoring market. ESCONDIDO, CA / ACCESSWIRE / February 23, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), in an ongoing effort to expand its outreach in the Ambulatory Remote Cardiac Diagnostic Monitoring Services market in the United States, is pleased to announce a definitive purchase agreement to acquire Cardiolink...

Read more

Apollo Endosurgery to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

February 22, 2021 4:30 PM

AUSTIN, TX / ACCESSWIRE / February 22, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 after the market closes. In conjunction with the release, Apollo...

Read more

Molecular Partners to Present at Upcoming Healthcare Investor Conferences

February 22, 2021 11:40 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / February 22, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will present at or attend several upcoming virtual healthcare investor events in February and March 2021. Conference Presentation Details: Event:...

Read more

Havn Life Announces DTC Eligibility of Its Common Shares in the United States

February 22, 2021 8:00 AM

VANCOUVER, BC / ACCESSWIRE / February 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce today that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United...

Read more

MJTV Wholly Owned Subsidiary, New England Biotech Accepts Delivery Of Post Secondary CBD Extraction Lines

February 18, 2021 11:30 AM

CHEYENNE, WY / ACCESSWIRE / February 18, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce its partner, Genesis Botanical Research (GBR), an MJTV Wholly Owned Subsidiary, took in the delivery of CBD extraction equipment. The post-secondary extraction lines are being erected at a temporary satellite location for assembly and fine-tuning. These lines will be moved to the Maine extraction facility once the structure is complete. As...

Read more

Viewpoint Molecular Targeting(TM) Enters into Long-Term Supply Agreement with the National Isotope Development Center of the U.S. Department of Energy Isotope Program

February 18, 2021 10:00 AM

Securing long-term supply advances development of Company's proprietary VMT-𝛼-GEN isotope generator, which enables a nimble supply of therapeutic radioisotopes with the power of alpha-particle therapy for cancer CORALVILLE, IA / ACCESSWIRE / February 18, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic...

Read more

CB Scientific Inc. Stock Symbol CBSC issues a Shareholder Update

February 18, 2021 7:00 AM

Current accomplishments and targeted goals have CBSC well-positioned for significant growth in 2021 ESCONDIDO, CA / ACCESSWIRE / February 18, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), is pleased to provide an update on the progress and achievements we have made since transitioning to the Ambulatory Remote Cardiac Monitoring market in June of 2020. While we have faced, like so many others, numerous unforeseen...

Read more

Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker

February 18, 2021 2:00 AM

CTCS HARVESTED BY PARSORTIX UNCOVER NOVEL METASTATIC BIOMARKER Parsortix system able to harvest difficult-to-detect mesenchymal CTCs Metastatic biomarker Cyr61 found by researchers in 40% of breast cancer CTCs may be a novel therapeutic target in treating drug-resistant breast cancers GUILDFORD, SURREY / ACCESSWIRE / February 18, 2021 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that...

Read more

Nascent Biotech Announces Successful Pritumumab In-Vitro Trial Data in Collaborative Covid-19 Treatment Study with Syracuse University

February 17, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / February 17, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company"), a clinical-stage biotech company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to announce the publication of strong In-Vitro study results from its research collaboration with Syracuse University. The data show that Pritumumab ("PTB")...

Read more

Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode

February 17, 2021 8:00 AM

VANCOUVER, BC / ACCESSWIRE / February 17, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), announces the departure of Ms. Barinder Rasode as President and as a director of the Company, effective immediately. The Company also announces that its Chief Executive Officer, Mr. Tim Moore, has been appointed as a director of the Company. Ms. Rasode commented, "We created Havn Life to benefit human...

Read more

Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases

February 16, 2021 9:00 AM

COLLEGE STATION, TX / ACCESSWIRE / February 16, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the results of an in vitro study of the Company's ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity. The Company's ITV-1 peptide was tested against human corona virus 229E Strain (HCoV-229E) and exhibited comparable efficacy but with a 20-fold lower toxicity than the widely used anti-influenza...

Read more

Helix BioPharma Corp. Appoints Dr. Frank Gary Renshaw To Scientific Advisory Board

February 16, 2021 8:00 AM

RICHMOND HILL, ON / ACCESSWIRE / February 16, 2021 / Helix BioPharma Corp. (TSX:HBP), ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced the appointment of Dr. Frank Gary Renshaw to the Company's Scientific Advisory Board. Dr. Renshaw is a healthcare industry executive and...

Read more

Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology

February 16, 2021 7:30 AM

PJSC Pharmsynthez is leveraging Xenetic's PolyXen® technology to improve the pharmacological properties of its Epolong product candidate pursuant to a royalty-bearing collaboration agreement Russian registration filing of Epolong, a polysialylated form of recombinant human erythropoietin, follows previously reported positive Phase 3 data for the treatment of anemia in patients with chronic kidney disease FRAMINGHAM, MA / ACCESSWIRE /...

Read more

Edesa Biotech Reports Fiscal First Quarter 2021 Results

February 16, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / February 16, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2020 and provided an update on its business. Earlier this month, the company announced that it has been awarded a C$14 million reimbursement grant from the Canadian government. The funds will...

Read more

Dyadic to Present at Upcoming Events

February 15, 2021 8:40 AM

JUPITER, FL / ACCESSWIRE / February 15, 2021 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company's management will be...

Read more

BIO-Europe Spring Connects the Right Partners at Europe's Largest Springtime Digital Life Science Partnering Event

February 15, 2021 4:20 AM

MUNICH, GERMANY / ACCESSWIRE / February 15, 2021 / The fifteenth annual BIO-Europe Spring(R) conference, the premier springtime partnering conference for the life science industry, again is delivered fully digital for its 2021 edition. With an expanded format to four 24-hour days the event will accommodate partnering meetings between attendees from all over the world. BIO-Europe Spring is produced by EBD Group, the leading partnering firm for...

Read more

eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients

February 11, 2021 5:15 PM

TUCSON, AZ / ACCESSWIRE / February 11, 2021 / Several recent publications have now highlighted the involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in the pathobiology of SARS-CoV-2 infection. In a comprehensive report published in the high impact journal CELL, of over 5,000 proteins identified as perturbed in COVID-19 patients who did not survive their illness compared to controls, NAMPT expression was linked to...

Read more

Hancock Jaffe Completes $41 Million Public Offering

February 11, 2021 4:05 PM

Capital Raise to Fund VenoValve U.S. Pivotal Trial IRVINE, CA / ACCESSWIRE / February 11, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully completed a public offering of its securities generating approximately $41.4 million of gross proceeds, prior to deducting underwriting discounts and commissions, and expenses. The...

Read more

Qrons Announces Launch of its New Website Reflecting Expanded Neuronal Diseases Goals

February 11, 2021 10:15 AM

NEW YORK, NY / ACCESSWIRE / February 11, 2021 / Qrons Inc. (OTCQB:QRON), an innovative biotechnology company developing next generation treatments for unmet neuronal diseases, using tissue engineering, stem cells and machine learning synergic technologies is proud to announce the launch of its newly redesigned web site at https://www.qrons.com The new site reflects Qrons' focus on extending its proprietary traumatic brain injury ("TBI")...

Read more